Cambridge, UK, 16 Feb 2022: o2h Ventures is pleased to announce an SEIS investment into Xploro®, a Manchester based company using augmented reality, gameplay, and artificial intelligence to deliver health information to young patients. 

Xploro reassures patients by clarifying what the upcoming procedure will accomplish, and assists in minimising procedural anxiety by enhancing health literacy and awareness about the treatment. Xploro has one of the highest ORCHA scores (Orcha seeks out the most popular digital health solutions and reviews them for compliance and best practice.)

Artificial Intelligence’s growing influence and role in revolutionising the healthcare business cannot be overlooked while discussing medical trends. Additionally, when AI is used to power AR(Augmented reality), the impact of AI opportunities becomes much larger and can positively affect society’s health system. 

o2h Ventures has a track record of supporting and investing in some of the UK’s most innovative early-stage biotech firms and this is o2h Ventures’ fourth investment into digital therapeutics.

Sunil Shah, CEO at o2h Ventures said: “Dom has amazing insight and passion to provide support for these young patients.  He has first hand experience for the needs and thus we are excited to support this investment from our newly launched SEIS fund.

Dom Raban, CEO at Xploro® said: “This investment from o2h Ventures supports Xploro in our mission to help children during treatment for a serious illness. It means we can continue to develop the platform and innovate in new ways and, in turn, offer its benefits to even more families. o2h were a great fit for us with their proven track record in Life Sciences and enthusiasm for what we’re doing”.

About Xploro®

Founded in 2019, Xploro® is an award winning and clinically verified health information mobile application that leverages augmented reality, games, and artificial intelligence to give health information to young patients in a way that empowers, engages, and informs them while having fun by putting health information in the hands by using language they understand and interaction paradigms that the patients are familiar with.

Xploro aims to reduce patients’ stress and anxiety and improve their clinical outcomes by reducing the fear associated with procedures and aim to reduce repeat procedures and shorten treatment times by enhancing  child health literacy. They provide the foundations for a generation of patients better able to self-manage their healthcare.

For more information, please see –

About o2h Ventures

The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information or to invest in the fund, please visit 


Media Contact:

Ayushi Vijayvargiya

Marketing Executive